JPM, Free Full-Text

The majority of breast cancers are oestrogen receptor-positive (ER+). In ER+ cancers, oestrogen acts as a disease driver, so these tumours are likely to be susceptible to endocrine therapy (ET). ET works by blocking the hormone’s synthesis or effect. A significant number of patients diagnosed with breast cancer will have the spread of tumour cells into regional lymph nodes either at the time of diagnosis, or as a recurrence some years later. Patients with node-positive disease have a poorer prognosis and can respond less well to ET. The nodal metastases may be genomically similar or, as is becoming more evident, may differ from the primary tumour. However, nodal metastatic disease is often not assessed, and treatment decisions are almost always based on biomarkers evaluated in the primary tumour. This review will summarise the evidence in the field on ER+, node-positive breast cancer, including diagnosis, treatment, prognosis and predictive tools.

JPM, Free Full-Text

JPM, Free Full-Text

JPMorgan Chase Email Virus - Removal and recovery steps (updated)

JPM, Free Full-Text

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes

JPM Stock Price and Chart — NYSE:JPM — TradingView

JPm Davao Condo Rentals

JPM, Free Full-Text

PPT - JPM NBC CA Requirements PowerPoint Presentation, free

At Any Rate J.P. Morgan Global Research

Insights Now J.P. Morgan Asset Management

JPMorgan Chase Keeps Growing. How It Stacks Up, in 11 Charts